Immunohistochemical Detection of CD10 with Monoclonal Antibody 56C6 on Paraffin Sections

Kaufmann, O.; Flath, Bernd; Späth‐Schwalbe, E.; Possinger, K.; Dietel, Manfred

doi:10.1093/ajcp/111.1.117

Cited by 57 publications

(29 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bcl-6 and CD10 are both markers of follicle center cells and are immunoreactive in noncutaneous follicle center lymphomas (16,40,41 (33). CD10 immunoreactivity is in keeping with Norton's (8) view that the true FCL of the skin have a similar immunophenotype to nodal FCL.…”

Section: Discussionsupporting

confidence: 78%

Cutaneous Follicle Center Lymphoma: A Clinicopathologic Study of 19 Cases

et al. 2001

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Cutaneous Follicle Center Lymphoma: A Clinicopathologic Study of 19 Cases

et al. 2001

View full text Add to dashboard Cite

“…NEP was identified using a mouse monoclonal antibody to human NEP/CD10 (56C6, Novocastra Laboratories, Newcastle, UK) at a dilution of 1:50. This monoclonal antibody is highly efficient for immunostaining of NEP even in paraffin-enbedded tissue sections [18, 19]. ET-1 was identified using a rabbit polyclonal antibody to human ET-1 (Peninsula Laboratories, San Carlos, Calif., USA) at a dilution of 1:500.…”

Section: Methodsmentioning

confidence: 99%

Imbalance between Neutral Endopeptidase 24.11 and Endothelin-1 Expression in Human Endometrial Carcinoma

Suzuki

Kikkawa²,

Ino³

et al. 2001

Oncology

View full text Add to dashboard Cite

Objectives: Neutral endopeptidase 24.11 (NEP)/CD10 is a cell-surface peptidase that degrades various bioactive peptides including endothelin-1 (ET-1). This enzyme is known to play a role in maintaining ET-1-regulated vascular homeostasis in the normal human endometrium. The purpose of the present study was to investigate the expression and localization of NEP and ET-1 in neoplastic endometria, and also to clarify the correlation of their expression with the tumor grade of endometrial carcinoma. Methods: Immunohistochemical analysis for NEP and ET-1 expression was performed on paraffin-embedded tissue sections of 7 normal endometria (after menopause), 5 atypical endometrial hyperplasias (AEH), and 32 endometrial endometrioid adenocarcinomas. Results: In normal endometrium and AEH, NEP immunoreactivity was detected in stromal cells, but not in glandular cells. In contrast, ET-1 immunoreactivity was detected in both glandular and stromal cells. In the stromal cells of grade 1 endometrial adenocarcinoma, NEP was detected at high or moderate quantities. However, significantly decreased NEP immunoreactivity was observed in the stromal cells of grade 2 and 3 adenocarcinomas. However, NEP was not immunostained in adenocarcinoma cells except for the lesions of squamous differentiation. ET-1 immunoreactivity was weakly detected in the stromal cells of grade 1 adenocarcinoma, but the intensity of ET-1 staining increased with advancing tumor grade. The ratio of the staining scores of stromal ET-1 to stromal NEP was positively correlated with the tumor grade. Conclusions: These findings demonstrate that NEP expression in the stromal cells of endometrial adenocarcinoma is downregulated, while stromal ET-1 is upregulated, with increasing tumor grade. The present findings also suggest that NEP may play a role in the regulation of neoplastic transformation, tumor progression, and differentiation in endometrial neoplasms, possibly by degrading certain peptide growth factors such as ET-1.

show abstract

“…Immunophenotypic methods have played an important role in the categorization of B-cell lymphomas into those of FCC or non-FCC origin because there are antigens that, even if not completely specific, characterize FCC as well as pre-and post-FCC. CD10 is expressed by precursor B cells as well as normal and many neoplastic FCC (7)(8)(9)(10)(11)(12)(13). Bcl-2 protein expression is another characteristic feature of neoplastic follicular centers, although there are many other normal and neoplastic bcl-2-positive lymphoid cells (14 -24).…”

mentioning

confidence: 99%

Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphomas

King¹,

Chen²,

Locker³

et al. 2000

Modern Pathology

View full text Add to dashboard Cite

Diffuse large B-cell lymphomas (DLBCL) are a biologically and clinically heterogeneous entity. Although some DLBCL represent transformation of follicular lymphomas (FL), the proportion that is of follicular center cell (FCC) origin remains uncertain. Immunophenotypic and genotypic markers used to suggest a FCC origin for a lymphoma (bcl-6 and CD10 expression, lack of CD138 expression, bcl-2 rearrangements [R]) or to subdivide DLBCL (bcl-2 expresssion, bcl-6 R) were therefore investigated in 22 FL and 44 DLBCL using paraffin section immunostains and Southern blot/polymerase chain reaction analysis. All FL tested were bcl-6؉ (19) and CD138؊ (22) with 16/19 also bcl-2 and CD10؉ (classic phenotype), one bcl2؉, CD10؊ (grade III) and two bcl2؊, CD10؉ (grade II or III). Bcl-2R was identified in 4/5 FL-GrI, 3/6 FL-GrII, and 1/3 FL-GrIII. Bcl-6R was found in 0/5, 2/4, and 0/3 FL, respectively. All but 3/41 DLBCL were bcl-6؉ with 17/37 also bcl-2؉ and CD10؉. Three of these cases were also CD138؉. Twelve bcl-6؉ cases were bcl-2؉, CD10؊, six bcl-2؊, CD10؉, and two bcl-2؊, CD10؊. The three bcl-6؊ cases were bcl-2؉, CD138؊ and two were CD10؉. Bcl-2R was identified in 5/27 DLBCL with 4/5 bcl-2؉, 3/4 tested CD10؉ and 4/4 bcl-6؉. Bcl-6R was identified in 7/26 including three with a classic FL phenotype. The vast majority of DLBCL in this study have an immunophenotype that supports a FCC origin. Although the proportion of DLBCL that co-expressed bcl-6, CD10 and bcl-2 was lower than for the FL, absence of bcl-2 or CD10 may be associated with higher grade FL. It is also possible that bcl-6 expression is not completely specific for a FCC origin. Only a minority of cases suggested postfollicular differentiation. Only a minority of DLBCL show bcl-2R, suggesting that many have a different molecular pathogenesis than most low-grade FL. Bcl-6R did not exclude a FCC origin. KEY WORDS: BCL-2; BCL-6; CD10; CD138; diffuse large B-cell lymphoma; follicular lymphoma; germinal center Mod Pathol 2000;13(11):1219 -1231Diffuse large B-cell lymphomas (DLBCL), as defined in the REAL and upcoming WHO lymphoma classifications, represent a heterogeneous entity that includes not only transformed (noncleaved or centroblastic) follicular center cell (FCC) lymphomas but also all other lymphomas composed of large and transformed B cells (1-3). The proposed WHO classification recognizes three relatively uncommon subtypes of DLBCL [mediastinal (thymic), intravascular, and primary effusion lymphoma] but the immunoblastic lymphomas, transformed/"high grade" marginal zone lymphomas of mucosaassociated lymphoid tissue (MALT) and presumably nodal types and all other types of transformed B-cell lymphomas are not distinguished from one another. The DLBCL were grouped together for two main reasons. First, it was difficult to reproduce some of the previously described morphologic distinctions (such as those between transformed FCC lymphomas and immunoblastic lymphomas). Second, it was unclear how, for example, large noncleaved (LNC) FCC/centroblastic lymphomas should ...

show abstract

Immunohistochemical Detection of CD10 with Monoclonal Antibody 56C6 on Paraffin Sections

Cited by 57 publications

References 9 publications

Cutaneous Follicle Center Lymphoma: A Clinicopathologic Study of 19 Cases

Cutaneous Follicle Center Lymphoma: A Clinicopathologic Study of 19 Cases

Imbalance between Neutral Endopeptidase 24.11 and Endothelin-1 Expression in Human Endometrial Carcinoma

Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphomas

Contact Info

Product

Resources

About